Silo Pharma ( ($SILO) ) has shared an announcement. On July 8, 2025, Silo Pharma, Inc. entered into an Agreement with the University of Maryland, ...

Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel ...

Silo Pharma files a patent for SPC-14, an intranasal Alzheimer’s treatment targeting specific brain receptors. Quiver AI Summary. Silo Pharma, Inc. has announced the filing of a patent ...

Silo Pharma, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent related to biomarkers for the efficacy of prophylactic treatments against ...

Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ:SILO) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its ...

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders ...

Silo intends to pursue the FDA’s streamlined 505(b)(2) pathway for approval of SP-26. Eric Weisblum , Chief Executive Officer of Silo Pharma, commented “Many chronic pain sufferers are seeking ...

Silo Pharma Inc SILO shares are trading lower by 31% to $1.55 during Wednesday’s session after the company announced it has entered into agreements to sell 917,432 shares of common stock at $2. ...

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected ...